Janux Therapeutics

Janux Therapeutics

  • Founded: 2017
  • Location: La Jolla, CA
  • Employee range: 1 - 10
  • Clinical stage: Clin1
  • Therapy area: Prostate cancer
  • Drug types: ONC
  • Lead product: JANX007
  • Product link: https://www.januxrx.com/developement-pipeline/
  • Funding: $60M stock Jul 2023; $222M IPO Jun 2021; $125M B Apr 2021; $56M A Mar 2021



job board

Short description:

Immunotherapies for Cancer

Drug notes:

JANX008 Clin1 colorectal cancer, NSCLC, SCCHN; TROP2-TRACTr RD cancers; JANX009 RD solid tumors

Long description:

Janux Therapeutics is developing tumor-activated immunotherapies to treat cancer. Current T cell therapies are limited by toxicity and efficacy, particularly for treating solid tumors. Using their platform masking technology, Janux is creating bispecific molecules that are designed to stimulate the immune system only within the tumor microenvironment, reducing the damage to a patient’s healthy tissue. As the molecules are modular, several elements of their technology can be swapped, enabling Janux to rapidly develop new drug candidates. Janux’s lead candidate, JANX007 is in clinical trial development for patients with prostate cancer.


Janux Therapeutics
Scientist, Downstream Process Development
San Diego, California|66 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com